Zhongshan, Guangdong-based Akeso Pharmaceuticals obtained its first investigative new drug (IND) application approval from the US FDA on April 2 for its lead asset, AK104, a PD-1/CTLA-4 bispecific antibody.
China Unbound: Second In A Series
China has seen explosive growth in developing new drugs ranging from antibodies to cell therapies, hence the first report from a new series covering emerging biotechs in China. They range from anti-cancer developers to respiratory specialty firms, from Shanghai to Zhongshan – several made-in-China biopharma innovators that largely have been flying under the radar
With this IND, Akeso’s founder and CEO Michelle Yu Xia has advanced within a niche in an increasingly crowded field, with its dual checkpoint inhibitor bispecific antibody in combination with two
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?